Back Clear search

The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Myocardial dysfunction - Heart failure

I.a

Left or biventricular dysfunction/failure

II - Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)

II.a

Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
II.l

Cardiac- cardiorespiratory/pulmonary arrest

III - Myocardial ischemia - Coronary artery disease

III.a

Coronary artery disease (acute) - Myocardial ischemia/infarction

V - Myocarditis

V.a

Myocarditis (can be fulminant)
V.b

Eosinophilic myocarditis
V.f

Myopericarditis (see under XIIc/d/g)
V.h

Relapse of previously diagnosed myocarditis

VI - Cardiomyopathy

VI.c

Takotsubo (stress) cardiomyopathy

VII - Cardiotoxicity

VII.a

Cardiotoxicity

X - Pulmonary edema - ALI/ARDS

X.a

Pulmonary edema, cardiogenic

XI - Pulmonary vasculopathies

XI.a

Pulmonary arterial hypertension
XI.j

Pulmonary infarction

XII - Pericardial involvement

XII.a

Pericarditis (see also under XIIc)
XII.b

Pericardial effusion (w/wo tamponade)
XII.e

Constrictive pericarditis - Pericardial thickening

XIII - Thrombosis - Embolism

XIII.a

Pulmonary embolism - Venous thrombosis/thromboembolism

XV - Chest pain

XV.a

Chest pain (acute or subacute), lone or prominent

XVI - Hemorrhage - Bleeding - Hematoma

XVI.e

Alveolar hemorrhage (AH), diffuse AH (DAH)
XVI.h

Coagulopathy

XX - Vasculitis

XX.c

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
XX.d

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XXII - Acute respiratory/cardiorespiratory failure

XXII.b

ARDS - Acute lung injury

XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a

Pneumonitis (interstitial lung disease/ILD)
XXIV.b

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
XXIV.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV.j

Progression, acceleration or exacerbation of preexisting ILD/fibrosis
XXIV.w

Radiation recall pneumonitis
XXIV.aa

Unilateral interstitial lung disease

XXIX - Small airway involvement

XXIX.a

Bronchospasm - Wheezing - Asthma
XXIX.h

Exacerbation or deterioration of preexisting asthma

XXX - Imaging features

XXX.l

Imaging: Ground-glass opacities (GGO) / shadowing
XXX.p

Imaging: Asymmetrical, predominantly unilateral involvement
XXX.s

Imaging: A mosaic pattern of attenuation

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.b

Lupus - Lupus syndrome (see also Vd)
XXXVI.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)
XXXVI.h

Myasthenia gravis - Myasthenic-like syndrome
XXXVI.i

Guillain-Barré (or GB-like) syndrome (w/wo ARF)
XXXVI.j

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
XXXVI.n

A flare of preexisting immune-mediated systemic/rheumatic disease
XXXVI.x

Anti Jo1 syndrome
XXXVI.z

Protracted, prolonged anaphylaxis
XXXVI.ae

Polyarteritis nodosa-like condition

XXXVIII - Miscellaneous - Varia

XXXVIII.c

Antiphospholipid antibodies w/wo the APL syndrome
XXXVIII.q

Myopathy-Myositis-Polymyositis (see also under Xba)